AIM ImmunoTech Q2 FY26 net loss widens 35.6% to USD 3.79 million
AIM•Cash balance increases
Cash and cash equivalents rose to USD 9.9 million at June 30, 2026, up 231.7% from Dec. 31, 2025.
Revenue edges higher, R&D declines
Revenue edged up 4% to USD 26,000 while research and development expense fell 49.8% to USD 589,000.
General and administrative expense climbed 98% to USD 2.95 million, attributed to offering-related costs tied to multiple equity transactions.
Quarterly loss widens as costs rise
AIM ImmunoTech posted a net loss of USD 3.79 million for the quarter ended June 30, 2026, widening 35.6% year over year.
Operating loss widened 32.8% to USD 3.51 million as total costs and expenses rose 32.5% to USD 3.54 million.
